ArticleJournal of hematology & oncology2021
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
Article in Journal of hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.NPJ vaccines · 2026Article
- Alpha-Fetoprotein Stimulates Cleavage of Membranal MICA/B on Liver Cancer Cell Lead to Escape Immune Surveillance of Natural Killer Cells.Journal of cellular and molecular medicine · 2026Article
- Targeting pre-metastatic niche with inhalable dendritic cell vesicles to prevent breast cancer lung metastasis.Journal of nanobiotechnology · 2025Article
- Extracellular matrix protein 1 in cancer: multifaceted roles in tumor progression, prognosis, and therapeutic targeting.Archives of pharmacal research · 2025Review
- Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy.Science advances · 2025Article
- An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding.Cell reports. Medicine · 2025Article
- Optimized multi-epitope neoantigen human cytomegalovirus vaccine based on adenovirus vectors elicits potent antiviral immunity.Frontiers in immunology · 2025Article
- The war between the immune system and the tumor - using immune biomarkers as tracers.Biomarker research · 2024Review
- Ultrasound combined with microbubble mediated immunotherapy for tumor microenvironment.Frontiers in pharmacology · 2024Review
- Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.International journal of molecular sciences · 2023Article
- Therapeutic cancer vaccines: advancements, challenges, and prospects.Signal transduction and targeted therapy · 2023Review
- Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.Cancer immunology, immunotherapy : CII · 2023Article
- The safety and anti-tumor effect of multiple peptides-pulsed dendritic cells combined with induced specific cytotoxic T lymphocytes for patients with solid tumors.Frontiers in immunology · 2023Article
- GPC3 Promotes Lung Squamous Cell Carcinoma Progression and HLA-A2-Restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells.Journal of immunology research · 2023Article
- Novel potential therapeutic targets of alopecia areata.Frontiers in immunology · 2023Review
- The Structural Characterization and Immunomodulatory Activity of Polysaccharides fromNutrients · 2022Article
- Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine.Journal of hematology & oncology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD8
methodsThe immune Epitope database, Molecular Operating Environment software, and enzyme-linked immunosorbent assay were used for epitope identification. Flow cytometry, confocal microscopy, UPLC-QTOF-MS, and RNA-seq were utilized for evaluating immunity of PBMC-derived DCs, CD8
resultsWe identified novel HLA-A2.1-restricted extracellular matrix protein 1(ECM1)-derived immunodominant epitopes in which LA induced a potent immune response. We also found that LA-loaded DCs upregulated the frequency of CD3
conclusionsLA-induced immune antitumour activity through DC cross-activation with CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.